Principal Financial Group
MRTX

Principal Financial Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Principal Financial Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,784
Closed -$634K – 2534
2023
Q4 		$634K Sell
10,784
-567
-5% -$31.9K ﹤0.01% 1909
2023
Q3 		$494K Buy
11,351
+355
+3% +$12.7K ﹤0.01% 1953
2023
Q2 		$397K Sell
10,996
-1,176
-10% -$48.5K ﹤0.01% 2005
2023
Q1 		$453K Sell
12,172
-310
-2% -$13.9K ﹤0.01% 1985
2022
Q4 		$566K Buy
12,482
+1,192
+11% +$77.1K ﹤0.01% 1947
2022
Q3 		$789K Buy
11,290
+499
+5% +$36.9K ﹤0.01% 1875
2022
Q2 		$724K Buy
10,791
+703
+7% +$44.7K ﹤0.01% 1980
2022
Q1 		$829K Sell
10,088
-352
-3% -$36K ﹤0.01% 2015
2021
Q4 		$1.53M Sell
10,440
-3,643
-26% -$566K ﹤0.01% 1903
2021
Q3 		$2.49M Sell
14,083
-1,848
-12% -$297K ﹤0.01% 1831
2021
Q2 		$2.57M Sell
15,931
-40,812
-72% -$6.55M ﹤0.01% 1852
2021
Q1 		$9.72M Buy
56,743
+32,773
+137% +$6.49M 0.01% 1396
2020
Q4 		$5.26M Buy
23,970
+876
+4% +$189K ﹤0.01% 1544
2020
Q3 		$3.83M Sell
23,094
-613
-3% -$83.9K ﹤0.01% 1560
2020
Q2 		$2.71M Buy
23,707
+6,459
+37% +$626K ﹤0.01% 1627
2020
Q1 		$1.33M Buy
17,248
+2,364
+16% +$212K ﹤0.01% 1692
2019
Q4 		$1.92M Buy
14,884
+52
+0.4% +$5.02K ﹤0.01% 1732
2019
Q3 		$1.16M Buy
14,832
+857
+6% +$80.4K ﹤0.01% 1808
2019
Q2 		$1.44M Buy
13,975
+1,416
+11% +$110K ﹤0.01% 1785
2019
Q1 		$921K Buy
+12,559
New +$854K ﹤0.01% 1837
2018
Q4 		– Sell
-4,473
Closed -$211K – 2326
2018
Q3 		$211K Buy
4,473
+222
+5% +$12.4K ﹤0.01% 2157
2018
Q2 		$210K Buy
+4,251
New +$161K ﹤0.01% 2156

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Principal Financial Group's MRTX Position: Q1 2024 in Review

Principal Financial Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 10,784 shares — an estimated $634K sold.

Principal Financial Group first reported a position in MRTX in Q2 2018 and held it in 22 quarters. The position peaked at $9.72M in Q1 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Principal Financial Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Principal Financial Group sold 10,784 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $634K.
  • Principal Financial Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • Principal Financial Group's Mirati Therapeutics, Inc. Common Stock position peaked at $9.72M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.